CG
ZYNE

Cutler Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cutler Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed – – 6299
2021
Q4 		$0 Sell
100
-1,700
-94% -$6.29K ﹤0.01% 6375
2021
Q3 		$7K Hold
1,800
– – ﹤0.01% 4278
2021
Q2 		$9K Hold
1,800
– – ﹤0.01% 4030
2021
Q1 		$8K Sell
1,800
-2,040
-53% -$9.25K ﹤0.01% 4044
2020
Q4 		$12K Hold
3,840
– – ﹤0.01% 3090
2020
Q3 		$12K Buy
3,840
+740
+24% +$2.72K ﹤0.01% 2875
2020
Q2 		$10K Hold
3,100
– – ﹤0.01% 2905
2020
Q1 		$11K Sell
3,100
-1,700
-35% -$7.9K ﹤0.01% 2689
2019
Q4 		$28K Buy
4,800
+1,800
+60% +$12.3K ﹤0.01% 2016
2019
Q3 		$22K Sell
3,000
-3,700
-55% -$41.7K ﹤0.01% 2134
2019
Q2 		$90K Buy
6,700
+2,100
+46% +$24.2K 0.01% 1156
2019
Q1 		$24K Sell
4,600
-4,561
-50% -$22.2K ﹤0.01% 1923
2018
Q4 		$27K Sell
9,161
-11,661
-56% -$63.9K ﹤0.01% 1913
2018
Q3 		$186K Buy
20,822
+9,961
+92% +$76.5K 0.01% 881
2018
Q2 		$105K Sell
10,861
-1,346
-11% -$13.8K 0.01% 1124
2018
Q1 		$106K Buy
12,207
+6,807
+126% +$73.4K 0.01% 1144
2017
Q4 		$67K Buy
5,400
+1,000
+23% +$11.5K ﹤0.01% 1659
2017
Q3 		$36K Sell
4,400
-1,538
-26% -$16.3K ﹤0.01% 2569
2017
Q2 		$100K Buy
+5,938
New +$118K ﹤0.01% 1861
2017
Q1 		– Sell
-200
Closed -$3.97K – 7443
2016
Q4 		$3K Buy
200
+100
+100% +$1.35K ﹤0.01% 5438
2016
Q3 		$1K Buy
+100
New +$950 ﹤0.01% 6378

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's ZYNE Position: Q1 2022 in Review

Cutler Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 100 shares.

Cutler Group first reported a position in ZYNE in Q3 2016 and held it in 21 quarters. The position peaked at $186K in Q3 2018. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

  • Cutler Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 100 Zynerba Pharmaceuticals, Inc shares in Q1 2022.
  • Cutler Group first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2016 and held it in 21 quarters.
  • Cutler Group's Zynerba Pharmaceuticals, Inc position peaked at $186K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.